Shirkad tignoolajiyada caafimaadka ah oo diiradda saareysa horumarinta tignoolajiyada cusub ee cudurka kansarka hore, ayaa maanta ku dhawaaqday natiijooyin cilmi baaris oo cusub. Daraasad caafimaad oo ku saabsan kansarka beerka ayaa muujisay awoodda weyn ee biomarker-ka cusub ee LAM ee DNA-ga cusub ee methylation-ka si loo ogaado kansarka hepatocellular (HCC) Dareenka ogaanshaha waa 95% gaar ahaanna waa 97.5%.
Daraasaddan, shaybaarada 130 maadooyinka ayaa la soo aruuriyay, oo ay ku jiraan: 60 maadooyin oo laga helay kansarka hepatocellular (marxaladda I ilaa IV), 30 maadooyin oo aan lahayn cudur beerka, 10 Mawduucyo oo laga helay cudurka beerka ee aan fiicnayn iyo 30 maadooyinka laga helay kansarka naasaha, kansarka mindhicirka. ama kansarka sanbabada. DNA ayaa laga soo saaray muunada, DNA-da waxaa lagu bedelay bisulfite, iyo methylation DNA waxaa lagu qiyaasey iyadoo la isticmaalayo IvyGene platform. Kadib markaad dhamaystirto xog ururinta iyo falanqaynta dhammaan shaybaarada, indho tirka shaybaarada si aad u xisaabiso waxqabadka imtixaanka.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of kansarka mindhicirka samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
